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Abstract: Viral encephalitis is worldwide spread pathology with high morbidity and mortality. Its incidence is higher in 
children. Enteroviruses, varicella zoster virus and herpes simplex viruses are the most frequent agents. However, in spite 
of the use of modern microbiological and radiological methods, an etiological diagnosis is reached in less than 50% of 
cases, making a careful differential diagnosis with non viral brain diseases imperative. Pathogenesis is elusive and therapy 
continues to remain supportive in almost all cases, as the only virus-directed treatment is available for herpesvirus-related 
encephalitis and a role for steroids continues to be debated. Novel and more targeted therapies are eagerly needed. 
INTRODUCTION 
 Encephalitis is an inflammation of the brain parenchyma 
usually caused by bacteria or viruses, and often associated 
with meningitis. Viruses vary widely in their potential to 
produce central nervous system (CNS) infection: for exam-
ple, rabies virus inevitably and exclusively causes CNS dis-
ease, whereas encephalitis is a less common manifestation of 
infections caused by herpes simplex or varicella zoster vi-
ruses. The spectrum of brain involvement and the outcome 
of the disease are dependent not only on the specific patho-
gen, but also on the immunological state of the host and on a 
range of environmental factors. We will focus this review on 
the most relevant agents of clinically important viral en-
cephalitis: herpes simplex virus 1 (HSV-1), varicella zoster 
virus (VZV), enteroviruses, Epstein-Barr virus (EBV), Tick 
borne (TBE), human herpesvirus 6 (HHV-6), measles virus 
(MV, the agent of subacute sclerosing panencephalitis, 
SSPE), rabies, West Nile Virus (WNV), Human immunode-
ficiency virus (HIV). We will not consider more recently de-
scribed viruses, such as Nipah or Japanese encephalitis vi-
ruses, as these have been thoroughly examined in recent re-
views. Tables 1a-c list the main agents of viral encepha-
litidis. 
Epidemiology 
 Viral encephalitis is of public health concern worldwide 
because of its high morbidity and mortality as well as con-
siderable economic costs. Incidence varies between studies 
but is generally between 3.5 and 7.4 per 100,000 patient-
years [1], and is higher in children. Although both genders 
are affected, most studies have shown a slight predominance 
in males. Unfortunately, few population-based studies have  
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been done, the disease is underreported, and in many cases 
the cause remains obscure. Data on the incidence of different 
etiological agents are contradictory. For example, a collabo-
rative study done in Finland using gene amplification to de-
tect various viruses in CSF samples of 3231 patients with 
encephalitis, meningitis, and myelitis, reported VZV as the 
most frequently involved agent (29% of cases). HSV and en-
teroviruses accounted for 11% of cases each and influenza A 
virus for 7% of cases
 
[2]. In contrast, in a recent report from 
Turku (Finland) of 144 consecutive adults with encephalitis 
or aseptic meningitis, viral etiology was recognised in 72 pa-
tients; 46% of these cases were attributed to enteroviruses, 
31% to HSV-2, 11% to VZV, and 4% to HSV-1 [3]. The dif-
ference may be partly explained by the fact that in the latter 
paper, the authors examined only immunocompetent adults, 
patients with meningitis and encephalitis were analysed 
separately, and the 5-year study period was long enough to 
reduce effects of epidemics and seasonal variation. 
HSV-1/2 cause the most severe forms of infections of the 
human brain. Currently, herpes simplex encephalitis (HSE) 
is estimated to occur in approximately 1 in 250,000 to 1 in 
500,000 individuals per year [4]. In the US the estimated in-
cidence is approximately 1 in 300,000 individuals [4], simi-
lar to those in England [5] and Sweden [6]. HSE occurs 
throughout the year and in patients of all ages. Around one-
third of cases occurs between 6 months and 20 years of age; 
approximately half of the patients are older than 50 years [7]. 
Both genders are equally affected. 
Pathogenesis and Histopathology 
 Viruses access the CNS by either the neuronal or haema-
togenous route [8-10]. The latter is most common and in ar-
thropod-borne infections is associated with alterations of the 
blood-brain barrier. In TBE transient viraemia follows viral 
replication in the skin after an insect bite, with consequent  
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Table 1. Selected Etiologic Agents of Viral Encephalitis 
 
(a) DNA Viruses 
 
Herpes Simplex Virus (HSV) 
Varicella- Zoster Virus (VZV) 
Epstein-Barr Virus (EBV) 
Cytomegalovirus (CMV) 
Herpesviridae 
Human Herpes Virus-6 (HHV-6) 
JCV 
Polyomaviridae 
BKV 
Adenoviridae Adenovirus 
 
(b) RNA Viruses 
 
Picornaviridae Enteroviruses Poliovirus 
Retroviridae Human Immunodeficiency Virus-1/2 (HIV-1/2) 
Rabdhoviridae Rabies 
Mumps 
Paramyxoviridae 
Measles 
 
(c) Arbovirus Group 
 
Eastern Equine Encephalitis (EEE) 
Western Equine Encephalitis (WEE) Togaviridae 
Venezuelan Equine Encephalitis (VEE) 
St Louis Encephalitis (SLE) 
West Nile Virus (WNV) 
Japanese Encephalitis (JE) 
Powassan Virus (POW) 
Murray Valley Encephalitis (MVE) 
Far Eastern Subtype  
(FE-TBEV) 
Siberian Subtype (S-TBEV) 
Flaviviridae 
Tick-Borne  
Encephalitis Viruses  
(TBEV) 
Western Subtype (W-TBEV) 
California Virus 
California Group 
La Crosse Virus (LAC) 
Bunyaviridae 
Sandfly Fever Group Toscana Virus (TOSV) 
 
invasion of the reticuloendothelial system. Secondary virae-
mia leads to infection of other organs, including the CNS. In 
acute viral encephalitis, a remarkable pathological finding is 
the infiltration of mononuclear inflammatory cells in the 
Wirchow-Robin spaces and in the meninges around the wall 
of vessels (perivascular cuffing). With further disease pro-
gression, astrocytosis proliferation and hypertrophy of mi-
croglial cells with formation of microglial aggregates (mi-
croglial nodules) and neuronophagia (clusters of microglial 
cells surrounding a dead neuron) become prominent histopa-
thological findings. The majority of inclusions are intranu-
clear but the only pathognomonic one is the intracytoplasmic 
Negri body in rabies. The pathologic changes induced by 
replicating HSV include ballooning of infected cells and in-
tranuclear eosinophilic amorphous or droplet-like bodies sur-
rounded by a clear halo, with chromatin margination at the 
nuclear membrane (Cowdry type A inclusions). Intranuclear 
type A inclusions are similar in HSV, VZV and CMV; a bet-
ter identification of the viral particles is obtained through 
electron microscopy, immunohistochemical and in situ hy-
bridisation techniques. An influx of mononuclear cells in in-
fected tissue ensues. HSE is associated with acute inflamma-
tion, congestion, and/or haemorrhage, most prominently in 
temporal lobes and usually asymmetrically in adults. Adja-
cent limbic areas are also involved, and the meninges overly-
ing temporal lobes may be congested. Approximately two 
weeks later, frank necrosis of the involved brain areas occur. 
 Access to CNS by the intraneuronal route occurs typi-
cally in rabies (limbic system), and in HSV infections. Once 
the virus has reached the brain, it may remain confined to a 
few cells or spread to adjacent tissues either by cell-to-cell 
transmission or through extracellular spaces; afterwards, 
HSV may remain in a latent state within the CNS [11, 12]. 
 Though largely investigated, the pathogenesis of HSE in 
children older than 3 months, adolescents and adults remains 
somewhat obscure. Both primary (in around one-third of the 
cases, generally younger than 18 years of age) and recurrent 
HSV infections can cause encephalitis. Of the two-thirds of 
cases occurring in the presence of pre-existing antibodies, 
only 10% of patients have a history of recurrent herpes labi-
alis. Patients with pre-existing antibodies are thought to have 
HSE as a consequence of HSV reactivation [13]. Interest-
ingly, when the genomic DNA from peripheral (labial) and 
CNS isolates are compared by restriction analysis, usually 
identical, but also different isolates are recovered [14]. The 
access of HSV to CNS in primary infection is still debated, 
with both the olfactory and trigeminal nerves proposed as 
prevailing routes. In patients with HSE, HSV particles have 
been demonstrated by electron microscopy along the olfac-
tory tract in some individuals [15, 16]. Animal models sup-
port the view that the olfactory tract provides an entry route 
into the CNS thus causing localisation of infection in brain 
regions analogous to the medial temporal structures of hu-
mans [17, 18]. Where does reactivation of latent virus occur? 
Reactivation within the brain tissue has not been demon-
strated. Although it has been proposed that this event takes 
place in the olfactory bulb or the trigeminal ganglion, with 
subsequent neuronal transmission to the CNS [17], it should 
be noted that HSE is rarely associated with recurrent herpes 
labialis. What about host immunity? It is conceivable that the 
CNS is particularly prone to HSV infection since intraneu-
ronal spread hides the virus from host defence mechanisms. 
The picture is further complicated by the observation that the 
HSE prevalence is the same both in normal and immunosup-
pressed hosts. However, the presentation is atypical in im-
munosuppressed individuals with a subacute and progres-
sively deteriorating course [19]. 
Clinical Presentation 
 Viral encephalitis can present in forms of low or mild se-
verity that heal spontaneously or in much more aggressive 
forms with a poor prognosis and severe neurological seque-
lae in survivors. The prodromal signs and symptoms are 
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those of a classic viral infection: fever and headache, possi-
bly accompanied by lymphadenophathy, nausea or vomiting. 
After a few days, symptoms of CNS involvement become 
manifest with altered mental status, considerable irritability 
and agitation, personality changes; seizures (focal or general-
ised) may occur, sometimes accompanied by focal neuro-
logical signs. Patients may then become lethargic or coma-
tose; death eventually ensues. Stiff-neck is a sign of menin-
geal involvement. 
 Fever is one of the most frequent features at presentation, 
and its absence should cast doubts on diagnosis. Prognosis is 
poorer in infants younger than 1 year and adults over 55. 
Young children may have a stormy course for several days 
because of severe cerebral oedema. 
Enterovirus Encephalitis 
 Enteroviruses seem to account for the majority of cases 
of viral encephalitis both in children and adults [20]. Infec-
tion is seasonal in temperate climates (summer and autumn 
peaks) but high the year round in tropical and subtropical 
climates. Although enteroviral encephalitis may be accom-
panied by mucocutaneous manifestations, including localised 
vesicles (e.g. hand, foot, and mouth disease), herpangina, 
and generalised maculopapular rash, these symptoms can be 
absent. Over the last 10 years, outbreaks of neurovirulent 
Enterovirus 71 have been reported from Japan, Malaysia, 
and Taiwan. A high mortality rate (19.3%) has been reported 
from Taiwan in children below 5 years of age [21].
 
 Unfavourable outcomes (death or neurological sequelae) 
of enteroviral encephalitis have been associated with 
younger age (< 4 years), high peak leukocyte counts ( > 
13,000/mm
3
), seizures, skin rash, myoclonic jerks, lower 
CSF viral yield rate, oral ulcers, enterovirus 71 as etiologic 
agent [21].
 
Herpes Simplex Encephalitis (HSE) 
 In HSE grey matter dysfunction of temporal and frontal 
lobes is a dominant feature, and the disease presents with 
personality changes, confusion, and disorientation. Seizures 
occur in half of the patients, focal neurological signs (hemi-
paresis) in about a third. Since prognosis is dependent on 
early initiation of treatment, there is a need for immediate 
and accurate diagnosis. For this reason, lumbar puncture 
should be preceded by neuroimaging only when focal neuro-
logical signs are present. CSF is abnormal in more than 95% 
of HSE cases; moderate pleocytosis is found, usually both of 
mononuclear white blood cells and red blood cells, the latter 
due to the haemorrhagic nature of the infectious process. 
Varicella Zoster Encephalitis 
 VZV encephalitis occurs mainly in young adults and in-
fants [22]. Seizures occur in 29 to 52% of cases. Focal neu-
rological abnormalities include ataxia, hypertonia or hypoto-
nia, hemiparesis, and positive plantar responses. Mortality 
varies from 5 to 10% [23]. Intranuclear inclusions and 
haemorrhagic necrosis, suggestive of varicella encephalitis, 
have been reported also in immunocompromised patients 
and in neonates [24]. 
Epstein Barr virus (EBV) Encephalitis 
 EBV encephalitis may involve not only temporal lobes 
but also different sites, including the cortex, brainstem and 
basal ganglia. Importantly, signs and symptoms of infectious 
mononucleosis, such as pharyngitis, adenopathy, sple-
nomegaly, and atypical lymphocytosis are often absent [25, 
26]. IgM against viral capsid antigens can be undetectable 
[27]. CSF abnormalities, if present, are subtle, with mild in-
crease in pressure, mild mononuclear pleocytosis ( 300 
cells/mm
3 
in one series) [26] and slightly elevated proteins. 
Diagnosis is suggested by the occurrence, in more than a 
third of patients, of movement disorders, such as chorea, and 
focal disturbances (hemiparesis) [26]. Although EBV en-
cephalitis runs frequently a benign course, neurologic seque-
lae may occur [26]
 
and the disease can occasionally be fatal 
[27]. 
Human Herpesvirus 6 (HHV-6) Encephalitis 
 HHV-6, the causal agent of exanthema subitum, infects 
nearly all children by 3 years of age; two variants, A and B, 
have been identified [28]. Both of them are neurotropic in 
vivo and reside latently in the adult brain, complicating at-
tempts to link HHV-6 to neurological disease [29]. However 
HHV-6 is considered a possible cause of encephalitis in im-
munosuppressed children. In patients undergoing allogeneic 
haematopoietic stem cell transplantation, a form of acute 
limbic encephalitis (characterised by anterograde amnesia, 
inappropriate ADH secretion syndrome, mild CSF pleocyto-
sis, temporal EEG abnormalities) has been linked to HHV-6 
[30]. Recently, HHV-6-associated rhombencephalitis, pre-
senting with seizures, ataxia, and myoclonus, has been de-
scribed in immunocompetent children [31]. Rare cases of 
encephalitis have been attributed to HHV-6 in adults [32-
37]. 
Tick-Borne Encephalitidis 
 Viruses transmitted to humans by tick-bite are important 
causes of CNS infections worldwide. TBE is caused by two 
strictly but biologically distinct flaviviruses. Seasonal out-
breaks occur in rural areas of Russia (Russian Spring-
Summer Encephalitis, RSSE) and in Central Europe (Central 
European Encephalitis, CEE); transmission is mediated by 
the hard ticks Ixodes persulcatus and Ixodes ricinus, respec-
tively (I. ovatus and I. gibosus may be additional vectors). 
The incubation period is 2 to 28 days. The clinical presenta-
tion of RSSE and CEE is similar, but RSSE is generally mo-
nophasic whereas CEE normally occurs in two stages. Se-
vere cases are more frequent in RSSE. Importantly, around 
30% of TBE patients do not recall any tick bite [38]. CEE is 
heralded by a few days of fever, headache, and muscle pain, 
followed by an asymptomatic period (2-10 days); later, 
symptoms and signs of encephalitis ensue. The mortality rate 
of RSSE is up to 25%, whereas in CEE it does not exceed 
4% [39]. Recovery from severe cases is slow, and 20% of 
patients may have severe neurologic sequelae. 
Measles Encephalitis 
 In MV infection, CNS involvement can occur early or 
late after acute measles, causing acute and subacute forms of 
encephalitis. Acute postinfectious measles encephalitis gen-
erally occurs in immunocompetent patients (mostly children 
and adolescents) during the exanthematic phase and within 8 
days after clinical onset [40]. The mortality rate is between 
10 and 20 %, while sequelae are observed in 20 to 40 % of 
patients who recover [40]. Onset of encephalitis at a later 
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phase results either in measles inclusion body encephalitis 
(MIBE) or in subacute sclerosing panencephalitis (SSPE). 
MIBE is a subacute/chronic neurologic disease that may be 
observed in immunosuppressed children and young adults. 
 SSPE is a demyelinating CNS disease occurring several 
years (generally 6-8) after acute measles infection, with a 
prevalence of 1 in 100,000 to 1 in 1 million infected chil-
dren. The disease has an insidious onset characterised by 
cognitive deterioration, poor school performance, ataxia, be-
havioural changes, myoclonus, possibly seizures, and chori-
oretinitis with partial visual deficit. Although progression 
differs in time and remissions may occur, death invariably 
occurs within 1 to 3 years [41]. Mutant MV strains (SSPE 
virus) can be recovered from the brain tissue of SSPE pa-
tients. 
Rabies 
 Rabies is the only human infection causing acute en-
cephalitis with a near-100% mortality rate. The incubation 
period varies from 5 days to over 6 months, but is usually of 
20-60 days [42]. After a prodromal period of malaise, anxi-
ety, pain or itching at the site of bite, and fever, patients de-
velop encephalopathic (hyperactivity and characteristic hy-
drophobic spasms of the sternomastoid, diaphragm and other 
inspiratory muscles, typical of the so called ‘furious rabies’) 
or paralytic neurological signs. Respiratory and heart failure 
following hydrophobic spasms are deadly in one-third of 
cases. Other clinical findings include Cheyne-Stokes respira-
tion, III, IV and IX cranial nerves palsies and signs of the 
amygdaloid nuclei damage. Intermittent episodes of halluci-
nations and maniacal behaviour are also observed. Without 
intensive care, the illness leads to coma, flaccid paralysis and 
death in few days from onset. 
West Nile Virus 
 West Nile virus, a flavivirus maintained worldwide in an 
enzootic cycle and transmitted primarily between avian hosts 
and mosquito (genus Culex) vectors, can occasionally infect 
humans, but most individuals remain asymptomatic. Symp-
toms may develop in 20-40% of subjects [43, 44] after an 
incubation period of 2-14 days. The vast majority of symp-
tomatic patients present with flu-like symptoms (West Nile 
fever), i.e. fever, headache, malaise, myalgia, fatigue, skin 
rash, lymphadenopathy, vomiting, diarrhoea [45]. Less than 
1% of infected individuals develop neuroinvasive diseases, 
i.e. meningitis, encephalitis, and/or acute flaccid paralysis. 
Although clinical features of these syndromes may overlap 
in the same patient, a large study of 228 patients found that 
most patients can be classified as either having meningitis or 
encephalitis and that patients with the latter have a higher 
mortality rate and more severe complications [46]. 
 West Nile encephalitis follows selective neuroinvasion in 
certain cell populations (substantia nigra in brainstem, basal 
ganglia [47] and cerebellum) and is characterised by altered 
consciousness, disorientation, focal neurological signs and 
symptoms (dysarthria, seizures, tremor, ataxia, involuntary 
movements, parkinsonism) [46, 47]. 
Human Immunodeficiency Virus 
 During primary HIV infection, neurological manifesta-
tions, ranging from severe and persistent headache to clinical 
signs suggestive of encephalitis and/ormeningitis, can occur. 
Headache and fever are prominent symptoms [48].
 
HIV-
RNA levels are high in cerebrospinal fluid. Although recov-
ery without antiretroviral drugs usually follows, these can be 
administered to try and speed it. 
 Patients with chronic HIV infection can also, albeit 
rarely, develop acute neurologic syndromes while having 
very elevated cerebrospinal fluid HIV loads. Resolution of 
symptoms after changes in, or initiation of, antiretroviral 
therapy occur [49]. 
Immune-Mediated Post-Infectious Inflammatory En-
cephalopathies 
 In addition to acute viral-induced brain damage, immune-
mediated inflammatory encephalopathies can be observed 
days to a few weeks after a viral (rubella, mumps, measles, 
EBV, VZV, influenza) or bacterial infection, but also follow-
ing vaccination, especially with smallpox and rabies vac-
cines. 
 This condition, named acute disseminated encephalo-
myelitis (ADEM), must be distinguished from infectious en-
cephalitis and non-infectious encephalopathies. ADEM is 
typically monophasic, with multifocal symptoms appearing 
within days, or sequentially over weeks, either in the pres-
ence or absence of fever and meningismus [50]. Neurologi-
cal symptoms (including focal motor and sensory deficits, 
optic neuritis, cranial neuropathies, seizures, myoclonus, and 
ataxia) mainly correlate with demyelinating white matter 
changes at brain MRI, although inflammatory foci affect the 
cortical and subcortical grey matter. An acute variant of 
ADEM, named acute hemorrhagic leucoencephalomyelitis, 
is a rare and usually fatal condition. ADEM and its variants 
should be differentiated from demyelinating-like, ischemic, 
and haemorrhagic lesions observed in large- and small-
vessel arteritis caused by VZV infection, and, in addition, 
from other demyelinating diseases, including multiple scle-
rosis-like syndromes associated with primary HHV-6 infec-
tion. In rare cases, transverse myelitis, optic neuritis, and 
neuromyelitis optica occur as isolated manifestations of 
ADEM. The range of post-infectious neurological complica-
tions is not limited to CNS, but includes also a bulbar variant 
of acute inflammatory demyelinating neuropathy (AIDP) af-
ter VZV infection, and acute brachial plexopathy in patients 
with antecedent CMV disease [51]. These disorders should 
be differentiated also from acute flaccid paralysis secondary 
to flaviviruses of the TBE complex, non-polio enteroviruses, 
coxsackievirus, and paralytic rabies. 
Non-Infectious Diseases Mimicking Viral Encephalitis 
 A wide spectrum of acute, subacute, and chronic medical 
conditions involving the CNS present with neurological
 
signs 
and symptoms that may overlap with those observed in the 
course of viral encephalitis, myelitis, and encephalomyelitis 
(Table 2). 
 While a detailed discussion of these disorders is beyond 
the scope of this review, we point to specific clues in clinical 
presentation, imaging findings and laboratory results that 
may be of help for differential diagnosis. In approaching a 
patient with suspected encephalitis it is important to define 
the neurological syndrome, assess whether the observed 
functional or structural CNS alterations involve the grey or 
white matter or both, obtain evidence of inflammation, and 
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rule out non-infective conditions. Typically, viral encephali-
tis presents as an acute febrile illness characterised by head-
ache, decreased consciousness, focal seizures and focal neu-
rological signs, as well as CSF markers of inflammation. 
Within this setting, acute viral encephalitis should be easily 
separated, on clinical grounds, from disorders causing asep-
tic meningitis, which manifests with fever, headache, cervi-
cal pain and neck stiffness.
 
However, differential diagnosis is 
not as simple as it may appear. HSE, for example, has gener-
ally an abrupt-onset with confusion, severe impairment of 
episodic and semantic memory, uni- or bilateral temporal 
seizures, often accompanied by other focal signs. In rare 
cases, fever may be absent [52]. However, at clinical onset 
the above clinical features - that reflect involvement of or-
bito-frontal brain regions and medial temporal lobes - may 
partly overlap with those observed in transient disorders, 
such as cerebral concussion, psychiatric conditions, transient 
global amnesia, and temporal seizures [53]. 
 In addition, a number of static disorders of the temporal 
lobe, including vascular, neoplastic, and infectious condi-
tions, may closely mimic the florid phenotype of HSE [53]. 
In particular, autoimmune limbic encephalitis (a subacute 
neurological syndrome characterised by cognitive impair-
ment, hallucinations, epileptic seizures, depression, and se-
vere memory deficit) must be considered in the differential 
diagnosis [54]. Further overlap with HSE and, in turn, with 
limbic encephalitis may occur in patients with steroid-
responsive encephalopathy associated with autoimmune thy-
roiditis (SREAT), also referred to as Hashimoto's encephali-
tis (a pleomorphic disorder characterised by high titres of 
antithyroid antibodies, hyperproteinorrachia, and variable 
EEG changes) [55]. Patients with SREAT present with 
acute/subacute myoclonus, altered consciousness, seizures, 
neuropsychiatric changes, and stroke-like deterioration. Im-
portantly, steroid-responsiveness is typical of SREAT and 
other encephalopathic disorders belonging to the group of 
‘nonvasculitic autoimmune meningoencephalitis’ (NAIM) 
[56], such as Sjögren’s syndrome and systemic lupus 
erythematosus. 
 In limbic encephalitis symptoms are secondary to dys-
function of the
 
limbic system (hippocampus, amygdala, hy-
pothalamus, insular
 
and cingulate cortex) as a consequence 
of cellular- and/or humoral-mediated autoimmune attack 
[57]. Limbic encephalitis is usually paraneoplastic, and 
mostly associated with distant and occult tumours, including 
small cell lung cancer, testicular seminomas, nonseminoma-
tous germ-cell tumours, and lymphoma. Importantly, in a 
substantial number of patients, limbic encephalitis is unre-
lated to cancer and in such cases it may well respond to 
treatment [58]. The diagnosis of autoimmune limbic en-
cephalitis is unequivocally obtained by demonstrating the 
presence of circulating autoantibodies recognizing either (a) 
intracellular onconeuronal antigens (e.g., Hu, Ma2, am-
phiphysin, and CRMP5/CV2), or (b) neuronal membrane an-
tigens (e.g., N-methyl-D-aspartate receptor, voltage-gated 
potassium channels) [54, 58]. 
 EEG recordings, magnetic resonance imaging (MRI) of 
the brain, and
 
CSF examination are the essential first steps 
for differentiating viral infection from limbic encephalitis, 
SREAT, NAIM, granulomatous diseases, and primary vascu-
litis. In cases where MRI is of little
 
help, brain positron 
emission tomography (PET) scan can provide diagnostic 
clues. Intriguingly, a limbic encephalitis syndrome, with 
confusion, altered sleep, temporal seizures, and memory im-
pairment has been reported in immunocompromised, trans-
planted patients with HHV-6 reactivation [59]. 
 Paraneoplastic conditions, such as brain-stem encephali-
tis, should be ruled out in the diagnostic workout of patients 
with rhombencephalitis, a rare brainstem syndrome present-
ing with myoclonus, ataxia, intention tremor, ocular distur-
bances, cranial nerve palsies, urinary retention, and, in fatal 
cases, neurogenic pulmonary oedema and shock. Rhomben-
cephalitis is usually associated with bacterial infections, in-
cluding Listeria monocytogenes, Mycoplasma pneumoniae,
 
and Borrelia burgdorferi. Sporadic, self-limited, and benign 
forms have also been attributed to HSV, influenza A, adeno-
virus, echovirus,
 
and flavivirus infections. In contrast, a rap-
idly evolving fatal course may occur following EBV and 
Table 2. Non-Infectious Diseases Mimicking Viral Encephalitis 
 
Condition Diagnostic Features 
Limbic Encephalitis 
Anti-Hu, -Ma2, -amphiphysin, -CRMP5/CV2 (all frequently associated with cancer), -VGKC, -NMDA 
receptor 
Hashimoto’s Encephalitis Anti-thyroid peroxidase, anti-thyroid microsomal antibodies  
Sjögren Sindrome Anti-SSA/Ro, -SSB/La antibodies 
Systemic Lupus Erythematosus (SLE) Anti-nuclear, -double-stranded DNA, antiphospholipid antibodies 
Acute Disseminate Encephalomyelitis (ADEM) Predominant demyelinating lesions at brain MRI  
Vasculitis of CNS CNS angiography, ANCA 
Bulbar Variant of GBS CSF albuminocytological dissociation  
Primary and Metastatic Brain Tumours CNS imaging 
Metabolic and toxic diseases Liver and renal function toxicology screening  
Epileptic status EEG recordings 
Abbreviations: ANCA: antineutrophil-cytoplasmic antibodies; CNS: central nervous system, CSF: cerebrospinal fluid; GBS: Guillain-Barré syndrome; EEG: electroencephalography; 
NCSs: nerve conduction studies; NMDA: N-methyl-D-aspartate; SSA: Sjögren syndrome antigen A; SSB: Sjögren syndrome antigen B; VGKC: voltage-gated potassium channels. 
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VZV infections. Recently, fatal outbreaks of enterovirus 71 
rhombencephalitis have also been reported [60]. 
Detection 
Viral Sequences in CSF Samples 
 Although over 100 viral agents can cause encephalitis, in 
clinical practice identification of the etiologic agent is still 
rare. Diagnosis was once accomplished by demonstrating 
intrathecally-produced antiviral antibodies. However, anti-
body assays are restricted to a few reference laboratories, 
require considerable time, and interpretation of results is 
complicated by the low antibody levels found in CSF as well 
as by passive transfer of antibodies from blood. This makes 
determination of CSF/serum antibody ratios mandatory. 
 Nowadays, nucleic acid (NA) technology is capable - in 
principle - of detecting genomes of any viral species. Mo-
lecular methods are characterised by the high sensitivity and 
rapidity (6 hours or less) that would allow the prompt initia-
tion of antiviral therapy. Indeed in CSF samples NA tech-
nology retains sensitivity for some time after initiation of an-
tivirals [61]. Since quantification of genome copy numbers 
may be a marker of disease severity and often predicts clini-
cal outcome, quantitative methods are being increasingly ap-
plied to estimate the viral load and to monitor, for some vi-
ruses (e.g., HSV), the effects of antivirals [62]. 
 Laboratory diagnosis begins with the NA extraction from 
CSF (rarely from brain biopsy). To this end, commercial 
methods are preferred for their effectiveness, and standardi-
sation. Recently introduced, automated methods based on 
NA-binding magnetic particles are characterised by high pu-
rity of extracted NA. In our experience, manual methods 
continue to be satisfactory due to the low numbers of speci-
mens usually submitted to laboratories for suspected en-
cephalitis. NAs are usually extracted with methods dedicated 
to either DNA or RNA. 
 While most laboratories use NA extraction kits with 
similar performance, gene amplification methods are highly 
diverse. The polymerase chain reaction (PCR) is the most 
common technique, but - for any given agent - several 
primer sets targeting different genes have been proposed by 
different authors. In addition, protocols differ with regard to 
reaction conditions, techniques for confirming amplified 
products, virus strains used as positive controls. Over the last 
few years, commercial methods for the most common viral 
agents have been introduced by major diagnostic Companies 
and are being evaluated the world over. Table 3 lists en-
cephalitis agents (some not examined in this review) with 
selected diagnostic molecular methods and relevant refer-
ences. A positive PCR result must always be considered in 
conjunction with clinical symptoms and signs prior to estab-
lishing a diagnosis. A negative RT-PCR result indicates only 
the absence of the agent being investigated in the sample, 
and does not exclude the suspected diagnosis. Equivocal re-
sults are those that fall between the lowest limit of detection 
and the background level. These can not be determined to be 
positive or negative. Qualitative PCR and RT-PCR are the 
amplification methods most frequently used. Both use ther-
mostable DNA polymerases, specific primer sets, and dedi-
cated thermocycling profiles. Amplicons are detected by gel 
electrophoresis and/or by hybridisation with a labelled probe. 
Real-time amplification (a technique that allows quantifica-
tion of amplified products) needs one or more primer sets 
plus photo-emitting probe(s) or, alternatively, a primer set 
plus a fluorescent dye that binds double-stranded DNA (e.g., 
SYBR Green). A recently proposed method is the loop-
mediated isothermal amplification (LAMP) assay. LAMP 
uses six or more primers that target a single gene. Its effi-
cacy, sensitivity, and simplicity have been proved for CMV 
[63]. 
 In clinical practice, laboratory diagnosis of viral encepha-
litis remains difficult due to the need of detecting a wide va-
riety of agents in a short time. Multiplex PCR methods (i.e., 
methods capable of detecting multiple targets in a single test) 
have been proposed [64-67],
 
but are rarely used. Notably, 
one system would allow the simultaneous detection of many 
enterovirus types, some herpesviruses and selected flavivi-
ruses [65]. The specificity and sensitivity of this system, 
however, have not been documented. 
Neuroimaging 
 Neuroimaging plays an important role in detecting in-
flammatory lesions of brain and meninges, since visualisa-
tion of typical lesion patterns does contribute to diagnosis. 
 In HSE brain CT scan reveals hypodense, contrast-
enhancing lesions in antero- and medial temporal and in in-
ferior frontal regions. Oedema and mass effect occur in 80% 
of cases. Brain MRI is superior to CT scan in detecting ne-
crosis in the orbitofrontal and medial temporal lobe, and in 
the insulae. Necrosis is demonstrated by increased signalling 
within the first 48 hours on T2-weighted (T2WI) or fluid-
attenuated inversion recovery (FLAIR) sequences [68] (Fig. 
1), with decreased T1 signal and variable enhancement. Dif-
fusion-weighted imaging (DWI) is even more sensitive than 
T2WI or FLAIR in detecting early cortical lesions in HSE, 
both in infants and adults [69]. Diffusion abnormalities dis-
appear within 14 days after onset, whereas hyperintensities 
on T2WI persist [69]. 
 In HHV-6 encephalitis, MRI shows predominantly me-
sial temporal lobe abnormalities, including T2 signal hyper-
intensities and early volume loss in the hippocampus [70, 
71].
 
DW-MRI is a promising tool for early detection and for 
outcome prediction [72]. 
 EBV encephalitis in adult immunocompetent patients 
produces normal or mildly swollen brain on MRI, while in 
infants, due to characteristic tropism to deep grey nuclei, a 
pattern of increased signal on T2WI in the bilateral thalami 
and basal ganglia is observed. 
 In acute measles encephalitis, T2WI reveals cortical oe-
dema and bilateral symmetric hyperintense lesions in pu-
tamen and caudate nuclei as well as in centrum semiovale. 
Contrast enhancement may appear in cortical areas and lep-
tomeninges [73]. In early stages of SSPE, MR spectroscopy 
demonstrates increased choline/creatine ratios suggestive of 
asymmetrical inflammation in parieto-occipital corticosub-
cortical regions. In the late stages, conventional MRI dis-
closes symmetrical periventricular hyperintense changes on 
T2WI [74]. 
 In patients with TBE, pathological T2-weighted and 
FLAIR MRI changes can be observed in almost 20% of  
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Table 3. Molecular Methods for Detecting the Main Agents of Viral Encephalitis [References in Square Brackets] 
 
(a) DNA Viruses 
 
Gene Amplification Method  Virus 
Qualitative PCR Quantitative PCR Multiplex PCR Other Techniques 
Herpes Simplex 
Virus (HSV) 
Target gene: DNA 
polymerase [61] 
Target gene: US4 
[99] 
Varicella-Zoster 
Virus (VZV) 
Target gene: gp29 
[61] 
Target region: 
ORF38 [99] 
Epstein-Barr Vi-
rus (EBV) 
Target gene: gp220 
[61] 
Target region: 
BNT143 [99] 
Target gene: DNA polymerase. 
PCR and chemiluminescent dot 
blot hybridization or hetroduplex 
mobility shift assay. Detection of 
herpesviruses and species identifi-
cation [101] 
Cytomegalo Vi-
rus (CMV) 
Target gene: MIE [61] Target gene: gB. LAMP [63] 
H
e
rp
e
sv
ir
id
a
e
 
Human Herpes 
Virus-6 (HHV-6) 
Target gene: U86, 
U95 [98] 
Target genes: 
CMV, UL54; HHV-
6, U56 [100] 
Target region: 
herpesvirus DNA 
polymerase. Si-
multaneous detec-
tion of enterovi-
ruses, herpesvi-
ruses and flavivi-
ruses. Broadly 
reactive primers 
for the three fam-
ily, then DNA 
probe array to 
differentiate virus 
species [65] 
Target gene: U67. Viral load in 
CSF, whole blood and serum. Dif-
ferentiation between primary in-
fection and viral integration. Dis-
tinction of 6A/ 6B variants 
through restriction analysis [102] 
JCV  Target gene: late 
mRNA [99] 
P
o
ly
o
m
a
v
ir
id
a
e
 
BKV  Target gene: VP3 
[99] 
Target gene: T 
large antigen [64] 
PCR and colorimetric hybridiza-
tion assay for differential detection 
of JC and BK virus genomes 
[103]. Commercially available. 
DNA microar-
ray:  
38 target genes 
for 13 encepha-
litis-producing 
viruses [104] 
A
d
e
n
o
v
ir
id
a
e
 
Adenovirus  Target region: L2p5 
precursor, E1B, L5 
pVI, hexon gene 
[99] 
  
 
(b) RNA Viruses 
 
Gene Amplification Method 
 Virus 
Qualitative PCR Quantitative PCR Multiplex PCR Other Techniques 
P
ic
o
rn
a
v
ir
id
a
e
 
Enteroviruses (EV) 
Polio and Several Non-
Polio EV are Included  
EV71 
Target gene: VP3-VP1. 
Seminested PCR. Species 
identification by sequencing 
[105] 
Target genes: 5’UTR for 
detection [106]. Species 
identification by microarray 
technology [107] 
Target region: 5’UTR. 
Detection of all EV 
[109] 
Target region: 5’UTR. Simulta-
neous detection of enteroviruses, 
herpesviruses and flaviviruses. 
Broadly reactive primers for the 
three family, then DNA probe 
array to differentiate virus species 
[65] 
 
R
e
tr
o
v
ir
id
a
e
 
Human Immunodefi-
ciency Virus-1/2 (HIV-
1/2) 
Commercial methods Commercial methods 
[110] 
 Real-time PCR-based 
point mutation assay 
for detection of drug 
resistance mutations 
[115] 
R
a
b
d
h
o
v
ir
id
a
e
 Rabies  Target gene: N. Quanti-
tative detection and 
distinction of different 
genotypes [111] 
  
Mumps Target gene: SH. Nested 
PCR and sequencing to per-
form genetic classification 
[108] 
Target gene: SH. One 
step assay with internal 
controls for nucleic 
acid extraction and 
PCR inhibitors [112] 
Target gene: HN; RT-LAMP 
[113] 
P
a
ra
m
y
x
o
v
ir
id
a
e
 
Measles   Target gene: N. Real Time ARMS 
PCR: six primer sets; genotypes 
differentiated by melting curve 
analysis [114] 
DNA microarray: 38 
target genes for 13 
encephalitis-producing 
viruses [104] 
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cases. Bilateral involvement of thalamus, and abnormalities 
of cerebellum, brain stem, basal ganglia, spinal cord are ob-
served [75, 76]. 
 Although the diagnosis of rabies is mostly clinical, MRI 
can be helpful. Both paralytic and encephalitic forms have 
similar distribution of mild T2 hyperintensities involving the 
brain stem, hippocampus, hypothalamus, deep and subcorti-
cal white matter, cerebral cortical grey matter, and basal 
ganglia. Alterations vary in different stages of the disease 
[77]. 
Management 
 The general management is essentially supportive and in 
severe cases must be in a high dependency or intensive care 
unit. Focal and generalised seizures need to be treated effec-
tively with anticonvulsants intravenously. Raised intracranial 
pressure must be treated with intravenous mannitol and/or 
steroids. In the case of rapidly increasing intracranial pres-
sure with clinical deterioration unresponsive to medical 
treatment, surgical decompression can be lifesaving. Other 
complications such as secondary bacterial infections, aspira-
tion pneumonia, respiratory failure, cardiac abnormalities, 
fluid and electrolyte imbalance must be detected early and 
treated appropriately. 
 Herpesvirus-related encephalitis can be treated with a po-
tentially effective antiviral therapy. The administration of 
acyclovir (within 48 hours of the onset of symptoms) at a 
dose of 10 mg/kg bw intravenously thrice per day for 14 
days (21 days in immunocompromised hosts) reduces both 
the mortality rate and long-term severe neurological conse-
quences in patients with HSE [78, 79]. However, mortality 
remains high (14%, increasing to 25.4% by the end of the 
(Table 3) contd….. 
 
(c) Arbovirus Group (RNA Agents) 
 
Gene Amplification Method 
 Virus 
Qualitative PCR Quantitative PCR Multiplex PCR Other Techniques 
Eastern Equine Encephalitis 
(EEE) 
Target gene: eeevgp2 
coding for P123, nsP3, 
nsP4 [116] 
Target gene: 
eeevgp3 coding for 
PE2, E2 [118] 
Target gene: 
eeevgp3 coding for 
PE2, E2. NASBA 
[116] 
Western equine encephalitis 
(WEE) 
Target gene: weevgp1 
coding for P123, nsP3 
[116] 
Target gene: 
weevgp2 coding for 
E1 [118] 
Target gene: 
weevgp coding for 
2E2. NASBA [116] T
o
g
a
v
ir
id
a
e
 
Venezuelan equine encephali-
tis (VEE) 
 Target gene: E1, E2, 
6K [120] 
 
 
St Louis Encephalitis (SLE) Target region: cap-
sid/preM [61] 
Target gene: 
nsP1, togaviru-
ses; NS5, flavivi-
ruses [122] 
 
West Nile Virus (WNV) Target gene: NS3 [61] 
Target genes: 
slevgp1, SLE; 
wnvgp1, WNV [66] 
 
Japanese Encephalitis (JE) Target gene: E. One step 
RT-PCR [117] 
 Target gene: E. RT-
LAMP [117] 
Powassan Virus (POW) Target gene: NS [61]   
Murray Valley Encephalitis 
(MVE) 
  
Target genes: 
wnvgp1, WNV; 
pol, JE. Real time 
PCR; probe 
common to JE 
and WNV [123]  
 
Far Eastern 
Subtype (FE-
TBEV) 
 
Siberian Sub-
type  
(S-TBEV) 
 
F
la
v
iv
ir
id
a
e
 
Tick-Borne 
Encephalitis 
Viruses 
(TBEV) 
Western Sub-
type  
(W-TBEV) 
Target region: NS5. RT-
nested PCR [118] 
Target region: 3’ 
UTR [121] 
Target gene: E. 
Three primer sets 
[67] 
Target region: 
NS5. Simultane-
ous detection of 
enteroviruses, 
herpesviruses 
and selected 
flaviviruses. 
Broadly reactive 
primers for the 
three families, 
then DNA array 
to differentiate 
virus species 
[65] 
 
California 
Virus 
   California 
Group 
La Crosse 
Virus (LAC) 
Target region: middle 
RNA [61] 
  
Target gene: M. 
NASBA [116] 
B
u
n
y
a
v
ir
id
a
e
 
Sandfly 
Fever 
Group 
Toscana Vi-
rus (TOSV) 
Target region: S and L 
segment 
[119] 
   
Abbreviations: PCR: polymerase chain reaction; RT-PCR: reverse transcription PCR; LAMP: loop-mediated isothermal amplification; NASBA: nucleic acid sequence-based ampli-
fication; Real time ARMS PCR: real-time amplification refractory mutation system PCR. 
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first year after treatment in Sweden over an 11 years period) 
[80], especially in patients with Glasgow coma score lower 
than 6. Patients under 30 years of age and with a Glasgow 
coma score above 10 have the best outcome. In immuno-
competent patients, herpesvirus resistance is rare and gener-
ally does not correlate with clinical outcome [81]. High dose 
steroids may be helpful in selected cases in children, espe-
cially when a biphasic course or relapses occur [82, 83]. 
 In VZV encephalitis, the treatment benefit of acyclovir 
used routinely in immunologically competent children has 
not been proved. IV methylprednisolone can be given to pa-
tients who present with neurological deficits with a delay af-
ter onset (> 7days) as these are likely to be cases of ADEM. 
 EBV encephalitis has no effective therapy (antiviral 
agents, immunoglobulins and steroids are ineffective). Dif-
ferent antivirals (ganciclovir, foscarnet and cidofovir) have 
been reportedly useful in few cases of HHV-6 encephalitis, 
but no clinical trials have been published [84]. No therapy 
exists for enteroviral encephalitis, although the broad-
spectrum antipicornavirus drug pleconaril might be an option 
in the future [85]. 
 Various antiviral and immunomodulatory agents have 
been used occasionally to treat SSPE with contradictory re-
sults. Encouraging results were reported in a multicenter 
study with a 6-month follow-up evaluating oral inosiplex 
(isoprinosine) alone or combined with intraventricular IFN-
2b therapy [86], but other studies are needed to confirm 
these data. 
 Rabies encephalitis is progressive and fatal, and therapy 
is largely palliative. Although survival has been reported in 
isolated cases of symptomatic patients, all of those patients 
had received either pre-or postexposure prophylaxis and 
none had positive test results for rabies virus [87-92]. Dis-
abling neurologic sequelae followed in nearly all of these 
survivors. In 2005, Willoughby and colleagues
 
described the 
survival of a nonvaccinated
 
young girl with encephalitic ra-
bies following an aggressive
 
treatment that included thera-
peutic coma, antiviral
 
therapy and intensive care support 
[93]. The strategy, known as the
 
Milwaukee Protocol, in-
volves administration of ketamine, midazolam,
 
amantadine, 
ribavirin and phenobarbitol, and is based on the idea that,
 
given sufficient time, antiviral and antiexcitatory therapy
 
will 
permit for viral clearance and clinical recovery.
 
However, in 
the case described by Willoughby and colleagues, the rabies 
virus was never isolated and diagnosis
 
was based on patient 
history, clinical findings and detection
 
of anti-rabies virus 
antibodies in the blood and cerebrospinal
 
fluid. Six addi-
tional cases of human rabies treated with the Milwaukee
 
Pro-
tocol have been described [94-97]. None of the patients had 
received postexposure prophylaxis, all patients presented 
with clinical disease, and none survived.
 
In spite of the detec-
tion of
 
anti-rabies virus antibodies in these patients and of 
evidence of viral clearance, autopsies of most
 
of the patients 
still revealed the presence of the rabies virus.
 
In conclusion, 
at present rabies encephalitis must continue to be regarded as 
an incurable condition. 
CONCLUSIONS 
 Viral encephalitis continues to pose many difficulties 
with regard to diagnosis and management. In spite of the so-
phisticated imaging and molecular methods today available, 
too often a cause is not identified. Supportive therapy to con-
trol seizures, respiratory arrest, cerebral oedema and to pre-
vent deep vein thrombosis, aspiration pneumonia, bacterial 
infections, gastrointestinal bleeding as well as disseminated 
intravascular coagulation still represent the mainstay of 
treatment. The pathogenesis remains largely elusive, and 
only one form (HSE) can benefit from treatment. The use of 
steroids as adjunctive therapy continues to be controversial, 
although a number of reports have shown clinical benefits. 
Novel methods have been recently proposed for viral identi-
fication; thus it is hoped that random DNA amplification 
coupled to other molecular techniques [87,88] will allow de-
tection of the multiple agents of encephalitis. 
 
Fig. (1). Coronal fluid-attenuated inversion recovery (FLAIR) MRI scan demonstrates: bilateral involvement of medial temporal lobes and 
right orbitofrontal region (arrows) in one case of HSV-1 encephalitis (A), and normal image of one age-matched control (B). 
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 Much needs to be done to improve the prognosis of viral 
encephalitis. Unfortunately, the rarity of the disease will 
likely prevent substantial efforts by drug companies to de-
velop novel and more targeted therapies. 
SEARCH STRATEGY AND SELECTION CRITERIA 
 Data for this review were identified by searches of Med-
line, Current Contents, and references from relevant articles; 
numerous articles were identified through searches of the 
extensive files of the authors. Search terms were "encephali-
tis" or "viral encephalitis" and “etiology”, “pathogenesis”, 
“diagnosis”, “symptoms”, “investigation”, “radiology”, 
“computerised tomography”, “nuclear magnetic resonance”, 
“positron emission tomography”, “single photon emission 
tomography”, “pathology”, “therapy”, “antiviral therapy”, 
“polymerase chain reaction”, “virology”, “cerebrospinal 
fluid”, “EBV”, “enteroviruses”, “herpes simplex virus”, 
“herpes zoster virus”, “HHV-6”, “measles”, “rabies”, 
“SSPE”, “West Nile Virus” or “tick borne”. Only English 
language papers published from 1960 to September 2008 
were reviewed. 
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